Researcher’s work on ‘kiss of death’ protein gets industry accolades
- Professor David Komander has won the 2023 GSK Award for Research Excellence in recognition of his work in uncovering the broad and important role the ubiquitin system plays in the human
- His research focuses on a form of protein modification called ubiquitination, which marks proteins for destruction, earning it the label the ‘kiss of death’.[1]
- The GSK Award for Research Excellence (ARE) is one of Australia’s most prestigious and longstanding awards available to the medical research
--------------------------------------------------------------------------------------------------------------------------------------------
Professor David Komander – Head of the Ubiquitin Signalling Division at WEHI – has won the 2023 GSK Award for Research Excellence (ARE), in recognition of his work in elevating global understanding of the ubiquitin system.
As a leading structural biologist, Professor Komander uncovered the key principles in ubiquitin chain assembly and disassembly. Ubiquitin is a protein that acts like a ‘tag’ to tell our cells which proteins to break down or recycle, an important ‘kiss of death’ process that helps our cells stay healthy and functional.[2] Professor Komander’s discoveries have allowed researchers to visualise different types of ubiquitin chains involved in recognition and disassembly of damaged proteins. This has led to new drug discovery projects across a range of conditions, including cancer, rare inflammatory diseases, and Parkinson’s disease.
In particular, the study of linear ubiquitin chains and their role in inflammation processes, has led the researcher to the discovery of a new protein that helps control inflammation, which was named OTULIN. This discovery further resulted in identification of a severe autoinflammatory disease, which has been named the OTULIN-related autoinflammatory syndrome (ORAS). ORAS is a very rare genetic disease, which can be life-threatening if not treated.[3]
Professor Komander and his team have recently been researching the link between early onset Parkinson's disease, a chronic and progressive disorder of the nervous system, and two proteins called PINK1 and Parkin as part of their studies into the ubiquitin system.
“Early onset Parkinson’s can be caused by genetic mutations that alter the function of key proteins. By understanding the molecular structures of these mutated proteins and monitoring how these proteins become activated and function, we have gained powerful insights into how Parkinson’s disease develops. Along the way, we contributed to some of the most important breakthroughs in the field in the last decade,” says Professor Komander.
Professor Komander’s research in this field has sparked collaborative work in the WEHI Parkinson’s Disease Research Centre. The centre works with movement disorder clinicians and consults with the Parkinson’s community to better understand the needs of those living with Parkinson’s and to guide research.
“Parkinson’s is the second most prevalent neurodegenerative condition, but its incidence is increasing faster than other neurological disorders. Importantly, there are no drugs that can stop disease progression,” says Associate Professor Grant Dewson, Head of the Parkinson’s Disease Research Centre.
“Defects in ubiquitin signalling are at the heart of neurodegenerative diseases such as Parkinson’s. David’s research has provided key insights into this and the role of PINK1 and Parkin in this highly complex disease. These proteins are the focus of international drug discovery efforts to stop or slow the progression of Parkinson’s and David’s research has unlocked this potential.”
There are estimated to be more than 200,000 people currently living with Parkinson’s disease in Australia, with one in five being diagnosed before the age of 50.[4] Professor Komander says his team’s work on the ubiquitin code is paving the way for the development of new therapeutic agents to treat Parkinson’s disease, which currently has no cure.
“We are really getting out of the academic mindset and moving towards more translatable outcomes. Enhancing our knowledge in this area has the potential to drive transformative improvements in health outcomes for patients living with other incurable diseases, including cancer,” says Professor Komander.
Professor Komander says the $100,000 AUD grant that comes with the GSK Award for Research Excellence will help take their research to the next level, especially as there are many areas of ubiquitination that have been under researched.
“Expanding our research into other molecules will open an entire new realm of what ubiquitination might be able to do. This grant will provide us with critical support as we take our research to the next level and build new methods for measuring ubiquitin modifications.”
“It’s an exciting time to be working within the field of ubiquitination. I am honoured to be named the 2023 recipient of the GSK Award for Research Excellence and have our work recognised in this way.”
The 2023 GSK Award for Research Excellence (ARE) was presented to Professor Komander at Research Australia’s Health and Medical Research Awards in Sydney this week. Dr Alan Paul, Medical Director at GSK Australia, said GSK is proud to support local Australian researchers who are at the forefront of improving health outcomes for patients in Australia and around the world.
“Professor Komander’s work is an outstanding example of how home-grown innovation is transforming our understanding and potential treatment of diseases like Parkinson’s that we once believed were incurable,” said Dr Alan Paul. “We are excited to support David and his team as they continue their critical research into the ubiquitin system.”
The GSK Award for Research Excellence is one of the most prestigious and longstanding independently-judged awards available to the Australian medical research community. It has been awarded since 1980, with over $3 million* awarded to local researchers since its inception.
Among the previous recipients of the GSK Award for Research Excellence are some of Australia’s most noted scientific researchers, including Professors Rinaldo Bellomo AO and Jamie Cooper AO (2021) and Mark Febbraio (2020). The 2022 GSK Award for Research Excellence was awarded to Professor Georgia Chenevix-Trench, Distinguished Scientist at The QIMR Berghofer Medical Research Institute, for her innovative research into mapping the genetics of breast and ovarian cancer.
ENDS
Enquiries or interview requests please contact:
Anastasiia Nazarenko Juliette Bagwell
anastasiia@palin.com.au juliette@palin.com.au
+61435 977 559 +61433 336 487
This media release has been issued by Palin Communications on behalf of GSK Australia
About GSK
GSK is a science-led global healthcare company. For further information please visit www.gsk.com/about-us.
References
*2023 value calculated from the respective yearly grant by adjusting for inflation
- Walter and Eliza Hall Institute for Medical Research. Pioneering ubiquitin researcher inducted as Academy Fellow, 2023. Available at: https://www.wehi.edu.au/news/pioneering-ubiquitin-researcher-inducted-as- academy-fellow/
- Walter and Eliza Hall Institute for Medical Research. Ubiquitin Signalling. 2023. Available at: https://www.wehi.edu.au/research/themes-and-divisions/healthy-development-and-ageing/ubiquitin- signalling/
- Fahrner L., OTULIN-Related Autoinflammatory Syndrome, 2023. Available at: https://www.dovemed.com/diseases-conditions/otulin-related-autoinflammatory-syndrome/
- Better Health Victoria. Parkinsons Disease. 2022. Available at: https://www.betterhealth.vic.gov.au/health/conditionsandtreatments/parkinsons-disease
